Biomedical Engineering Reference
In-Depth Information
Fig. 6
Inhibition of monocyte adhesion by siRNA to ICAM-1 or VCAM-1. (A) HCAECs were
transfected with anti-ICAM-1 or anti-VCAM-1 siRNA for 48 hr and then exposed with 200 μg/
mL cLDL for 16 hr. Control cells were treated with vehicle or 200 μg/mL nLDL. h e monocyte
adhesion was measured as described in the text. n = 3-4 per point, *P < 0.01, **P < 0.001 vs.
vehicle control cells pretreated with the same siRNA,
#
P < 0.05,
##
P < 0.01 vs. no siRNA control
cells (white bars) subjected to the same treatment. (B) Representative images of cells treated with
cLDL. Permission to publish obtained from Wolters Kluwer Health.
Color image of this i gure appears in the color plate section at the end of the topic.
CONCLUSION
Carbamylation is a non-enzymatic protein modii cation mainly by cyanate, a
metabolite of urea, which is normally present in human plasma and is elevated
in uremic patients. cLDL has several biological ef ects relevant to atherosclerosis.
Activation of ICAM-1 and VCAM-1 adhesion molecules and attraction of
monocytes to endothelial cells are some of the most prominent events. Other
ef ects include the induction of injury in human coronary artery endothelial cells
